A one-year hospital-based prospective COVID-19 open-cohort in the Eastern Mediterranean region: The Khorshid COVID Cohort (KCC) study

Study population

In this prospective hospital-based surveillance study, patients who were admitted for COVID-19 from February 2020 in the Khorshid Hospital in Isfahan were recruited. Khorshid is the referral hospital for COVID-19 adults in Isfahan (Fig 2). About fifty percent of the entire CVOID-19 population from Isfahan refers to this hospital.

• Download figure
• Open in new tab

Fig 2.

The scheme of the Khorshid COVID Cohort (KCC) study.

In this study, we diagnosed the COVID-19 patients base on the Chinese COVID-19 diagnosis and treatment guidelines, in addition to the WHO provisional advice [14]. Then, in case of a positive polymerase chain reaction (PCR) or compatible Chest computed High-resolution CT (HRCT) scan with COVID-19, the patients were recruited in this study. The ethics committee of the Isfahan University of Medical Sciences (IUMS) and the other national authorities approved the study (IR.MUI.MED.REC. 1399.029). The experimental protocol was also conformed to the Declaration of Helsinki. Also, the entire subjects gave informed consent to the experimental procedure. The informed consent was given by the first relative family of patients with severe conditions. This Cohort has two phases. The first phase is on the admission information on hospitalized patients until discharge or death, while the second phase is related to the patients who were discharged from the hospital for future symptoms or social factors. Six-hundred patients were enrolled in the first phase, while four-hundred ninety patients with complete information were analyzed in this paper.

Baseline information collection

We obtained the information related to demographic, socioeconomic status (SES), medical history, underlying chronic diseases, chest computed tomographic (CT) scans, signs, symptoms, laboratory findings, treatment (including oxygen support, antibiotics, antiviral therapy, corticosteroid therapy) during the hospital admission, and outcome data from patients medical records by Table 1 checklist. The body temperatures of the patients were taken at least four times a day. The detection of nucleic acid from the SARS-CoV-2 in upper respiratory specimens was qualitatively assessed using the PCR test. The PCR was performed once for admission.

Laboratory findings

Pharyngeal swab samples were collected for the COVID-19 test on arrangement. Blood samples were collected from each participant, and routine blood test, including Lymphocyte count (LYM), Platelet, Neutrophil (NEU), and White blood cell (WBC) counts, Na, K, BUN, CR, Ca, P and Mg were performed on the blood samples. Furthermore, blood biochemistry parameters such as C-reactive protein (CRP), Aspartate aminotransferase (AST), Alkaline phosphatase (ALP), Alanine aminotransferase (ALT), Urea, as well as lactate dehydrogenase (LDH) and Albumin were assessed using HITACHI 7600-020 automated biochemistry analyzer. Other requested parameters on admission included troponin and EKG.

Imaging protocol

We acquired the entire chest CT images using a 64-slice Philips scanner, with low-dose protocol, between patients in the supine position, without the injection of contrast, and at full inspiration. The images were evaluated by two radiologists with experience in thorax imaging. A senior investigator with at least ten years of experience at interpreting chest CT images resolved any disagreement. The following characteristics were recorded for each CT scan: distribution (craniocaudal, and transverse), the pattern, and disease severity according to a semi-quantitative scoring system [15]. Each CT scan was sub-classified according to published RSNA guidelines to the following four groups: typical, indeterminate, atypical, and negative [16].

Discharge criteria

Patients presenting the following criteria were discharged: per evaluation of the treating physician, the clinical symptoms significantly improved (respiratory rate<20, pulse rate<100, oxygen saturation of 92% while the patient was breathing ambient air), AND the body temperature to be returned to normal for more than two days without any antipyretic medications, AND normal swallow for the solid oral medication (whole tablets and capsules), AND passing until 14 days after the onset of symptoms for patients without suitable caring system, AND good facilities for quarantine at home [17].

Follow-up

The total follow-up time lasts for one year in our study (The 1st, 4th, 12th weeks, and the first year). The following information of the discharged patients are being recorded: clinical signs and symptoms at home, possible COVID-19 recurrence, underlying diseases in their family, psychological symptoms, sleep quality, and related problems (Table 2). Discharged patients are being followed up by telephone in the first and fourth weeks to obtain whether they had any symptoms presented in Table 2. In the 12th week and the first year, each patient attends the hospital to complete the Patient Health Questionnaire-9 (PHQ-9) and the Depression Anxiety Stress Scales (DASS-21) [18]. Moreover, clinical symptoms and the respiratory function (e.g., maximal inspiratory pressure (MIP), maximal expiratory pressure (MEP), and forced vital capacity (FVC), and forced expiratory volume one second (FEV1)) are being determined in the last two follow-ups.

We used the self-report PHQ-9 questionnaire to measure the depression severity, with the total scores labeled as the following: severe depression (15–21), moderate depression (10–14), mild depression (5–9), and no depression (0–4) [19]. Depression, Anxiety, and Stress (DASS-21), a.k.a. Mental health status was measured based on previous research [20]. Stress subscale was assessed using question numbers one, six, eight, eleven, twelve, fourteen, and eighteen. The total stress subscale score was separated into five groups: extremely severe stress (35–42), severe stress (27–34), moderate stress (19–26), mild stress (11–18), and normal (0–10). Anxiety subscale was estimated using question numbers two, four, seven, nine, fifteen, nineteen, and twenty. The anxiety subscale score was also divided into five groups: extremely severe anxiety (20–42), severe anxiety (15–19), moderate anxiety (10–14), mild anxiety (7–9), and normal (0–6). The depression subscale was formed using questions three, five, ten, thirteen, sixteen, seventeen, and twenty-one. The total depression subscale score was classified as extremely severe depression (28–42), severe depression (21–27), moderate depression (13–20), mild depression (10–12), and normal (0–9). It was shown that the DASS is a reliable and valid method in measuring mental health between the Iranian population [21]. Note that the DASS was previously used in the literature for the other version of coronavirus like SARS [22,23].

Outcomes

The initial results for the admitted patients were the following: Vital signs improvement, including SpO2, pulse and respiratory rate, blood pressure, temperature, intubation rate, death, and length of stay at the hospital. The secondary outcomes are impaired pulmonary function, later signs and symptoms, psychotic disorders, sleep disorders, and sustained end-organ failure. Moreover, The primary composite endpoint (PCEP), defined as death, the use of mechanical ventilation or admission to an intensive care unit (ICU) [24], is reported in this paper.

The research team of professionals from Khorshid Hospital and clinical faculty members of Isfahan University of medical sciences cross-checked the data. A trained team of researchers independently entered the data into a computer-based database. In a case of missing in the raw data, the coordinators were requested for clarification, to contact the corresponding clinicians. For patients who had consciousness problems on admission, we obtained data from their pre-admission information based on medical histories and through contact with their close relatives considering medical records from previous hospital visits. Further details of the KCC based on the STROBE statement were provided (S1 File).

Data analysis

First, we entered the data into the Epi-Info 3.5.3 program (https://www.cdc.gov/epiinfo/). Then, the data were analyzed using STATA v12.0 (StataCorp, College Station, TX). The patient characteristics were reported as a percentage for categorical and mean (SD) for continuous data. The endpoint in this study was death or cure from the entire COVID-19-related causes. We confirmed the endpoint by reviewing hospital medical registration, or by calling using the registered phone number. When the study period finishes, individuals alive after a follow-up time are censored. Accordingly, the subject outcome variable is death or censored after the follow-ups.

We use survival analysis to identify the connection between the patient’s attributes with time from initial admission to death or the end of the follow-up after discharge are considered as covariates. The life table is used to estimate survival after the first admission, and a log-rank test is used for survival curves comparison according to different events. Time-dependent Cox regression is used to calculate the adjusted hazard rate to determine independent predictors of time to death [25]. The significance level was set to p=0.05.

Results and discussion

Descriptive statistics were calculated for socioeconomic, demographic characteristics, clinical symptoms and health service utilization, contact history, and additional health information variables (Table 3). A total of 490 first COVID-19 cases with complete information were analyzed in this manuscript, with the average age of 56.58±15.09 years (39%, female) who were admitted to the Khorshid hospital from February 2020. Eight percent of the admitted patients were transferred to the intensive care unit (ICU) (48% male). Thirty-four patients (7%) died. The top three leading causes of admission were: fever (77%), dry cough (73%), and fatigue (69%). Sneeze (10%), runny nose (14%), and abdominal pain (17%) were the least frequent symptoms among COVID-19 patients. The top three prevalent comorbidities with COVID-19 were hypertension (35%), diabetes (28%), and ischemic heart disease (14%).

Table 3.

Table 3.

Among 490 COVID-19 patients, 90 patients had positive PCEP. The following characteristics were not significantly different in PCEP positive and negative groups: BMI, occupation, marital status, number of infected family members, smoking status, and travel history to the high-risk regions. However, the distribution of age (p<0.001), sex (p=0.010), symptom duration (p=0.010), and quarantine before admission (p=0.0140) were significantly different in PCEP positive and negative groups. Having analyzed the comorbidities in PCEP positive and negative groups, although hypertension, Ischemic heart disease, Immunological problems, COPD, and cancer were not significant, diabetes (p=0.026), and acute kidney disease (p=0.008) were significant.

Among signs and vital symptoms, only SpO2 (p<0.001), fatigue (p=0.020), and Sore throat (p=0.001), and were significantly different in both groups. However, except for Mg (p=0.500), and platelet count (p=0.051), other laboratory findings were significant in the analyzed groups. Notably, elevated white blood cells (p<0.001), and neutrophil counts (p<0.001), BUN (p=0.001), LDH (p<0.001), AST (p<0.001), ALT (p=0.002), ALP (p=0.001), and Cr (p<0.001) were seen in PCEP positive groups compared with the negative groups. However, the platelet counts decreased in the PCEP group, but it was not significant (p=0.051). Moreover, the lymphocyte counts significantly decreased in the PCEP positive class (p<0.001).

The median time from admission to discharge was 5.0 days (interquartile range 3.0-8.0). The transmission route was by a history of exposure to the epidemic area (16%) or close contact with family members (25%), among which 10% of patients had both exposures. The average symptom duration was 7.5 days. A significant reduction of this time was observed in PCEP positive group respect to the negative group (p=0.010). Representative samples of the COVID-19 patients were provided at https://figshare.eom/s/ef91187fb69a051b8396 (50 subjects with negative PCEP and 10 subjects with positive PCEP).

This Cohort aims to identify the problems presented in COVID-19 patients from the first-time admission until death or one year after discharge. It is the first study in which COVID-19 patients are followed up to identify trends in signs and symptoms in an outbreak hot zone in the Middle East, to the best of our knowledge. The results of the first one-hundred patients were presented. It is required to perform thorough research on the novel, appearing in human infectious coronaviruses. It is then possible to explain their pathogenic mechanisms route and to recognize potential medicine. When taking into account the social effects of the outbreak, it might be possible to develop useful preventive and therapeutic medicaments. Moreover, the long-term analysis of psychological distress and symptoms of mental illness of such patients after hospital discharge was taken into account in our Cohort. Such issues are fundamental, in general, in this pandemic [26].

According to our laboratory-confirmed cases, the common clinical manifestations were fever (77%), dry cough (73%), fatigue (69%), and shortness of breath (67%). The three most common clinical manifestations were consistent with the studies in China [7,24,27,28]. In laboratory examination results, less than 20% of the patients had decreased white blood cell counts. Also, the percentage of lymphocytopenia was 4%. It was in contrast with other studies that reported that most of their patients had this problem [24,29].

Previous studies demonstrated that the elderly and those with underlying disorders (i.e., cardiovascular diseases, diabetes, hypertension, and chronic obstructive pulmonary disease) developed rapidly into ARDS, even leading to ICU admission or death [7]. Although our findings presented that the rate of death and ICU admission was 7% and 14%, a similar condition was observed. Cardiac complications, including heart failure, arrhythmia, or myocardial infarction, are common in patients with pneumonia.

It might be possible to reduce the probability of COVID-19 incidence and distress, reporting high-risk pathogens, social effects of this disease, which can help the health policymakers for leading reasonable policies when using our cohort results. Most people show mild symptoms. However, it may progress to ARDS, pneumonia, and multi-organ dysfunction in older people and those with comorbidities [30]. Many patients who survive acute viral pneumonia have impaired functions and health status in the first few months of recovery. However, long-term sequelae are still mostly unknown [31]. Patients who survived an episode of ARDS may have marked dyspnea and severe respiratory physiological abnormalities. Although a one-year post-ICU follow-up study showed that survivors of A(H1N1)-associated ARDS had minor lung disabilities [32], both obstructive and restrictive deficits have been reported in patients with ARDS. The ARDS survivors often suffer prolonged myopathy limiting activities of daily living, posttraumatic stress disorder (PTSD), and increased number of deaths after apparent recovery. Such problems usually exist for more than three months. Moreover, many patients show continuous neurocognitive dysfunction for one to two years. When managing these problems supportively, the knowledge of the PTSD persistency in such patients is required [33].

The medical and public health infrastructure and the economy were affected by this new virus outbreak worldwide. Several studies have reported adverse psychological complications, including confusion, symptoms of traumatic stress, and anger in cases, who encountered stressful situations. The long quarantine period, fear of disease, boredom, despair, inadequate food shortages, insufficient information, stigma, and financial loss are known as stressors in the COVID-19 epidemic [34,35]. Along with this, the primary purpose of this study is to identify psychological problems among discharged patients for one year.

It takes time to see how the virus affects our lives here in Iran and other parts of the world. It is also possible to have similar future outbreaks. Besides limiting this outbreak, preventive programs must be planned for such problems. It is of great importance when considering the warning by the WHO chief as “the virus will be with us for a long time.”

It must be mentioned that self-reporting used for the first two follow-ups has some limitations in comparison with face-to-face interviews for the second and third follow-ups. Also, psychological studies do not necessarily probe psychological services efficacy. Thus, dynamic observations and more follow-ups are necessary. The larger sample size is also required for result verification, which is available during the Cohort. Apart from such limitations, it is possible to perform a risk assessment and to use medical data mining for diagnosis and prognosis to identify complex interactions.